PRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxRetrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/in Retrospective studies/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/in Clinical Trial, Metastatic, Phase 2/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/in Clinical Trial, Metastatic, Phase 2/by MaxTALAPRO-2 Trial: Final OS Analisys Confirms Talazoparib + Enzalutamide Effectiveness in mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Newsletter 12/2026 March 22, 2026
- JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC March 20, 2026
- AUTOTAC Degraders ATB‑238 and ATB‑239 Target AR and AR‑v7 in Advanced Prostate Cancer March 20, 2026
- ²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer March 20, 2026